227 related articles for article (PubMed ID: 11787388)
1. [Role of prebiotics and probiotics in therapeutic management of cryptogenetic inflammatory bowel disease].
Marteau P; Seksik P
Gastroenterol Clin Biol; 2001 Sep; 25(2 Pt 2):C94-7. PubMed ID: 11787388
[No Abstract] [Full Text] [Related]
2. [Probiotics in chronic inflammatory bowel disease].
Böhm S; Kruis W
MMW Fortschr Med; 2006 Aug; 148(35-36):30-4. PubMed ID: 16995360
[TBL] [Abstract][Full Text] [Related]
3. Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis.
Guslandi M
J Clin Gastroenterol; 2010; 44(5):385. PubMed ID: 20104184
[No Abstract] [Full Text] [Related]
4. [Maintaining remission of ulcerative colitis with the probiotic Escherichia Coli Nissle 1917 is as effective as with standard mesalazine].
Adam B; Liebregts T; Holtmann G
Z Gastroenterol; 2006 Mar; 44(3):267-9. PubMed ID: 16514573
[No Abstract] [Full Text] [Related]
5. Efficacy of a symbiotic product during clinical relapse of ulcerative colitis.
Guslandi M
J Clin Gastroenterol; 2011; 45(5):475-6. PubMed ID: 21336142
[No Abstract] [Full Text] [Related]
6. [Chronic inflammatory bowel diseases. Update on evidence-based therapy].
MMW Fortschr Med; 2005 Apr; 147(17):58-9. PubMed ID: 15903063
[No Abstract] [Full Text] [Related]
7. [Chronic inflammatory bowel diseases. Proven and innovative in the treatment].
MMW Fortschr Med; 2006 Jun; 148(24):43. PubMed ID: 16850809
[No Abstract] [Full Text] [Related]
8. [For treatment decision the age to be taken into account. In Crohn's disease and ulcerative colitis attention to be paid to the age at manifestation].
MMW Fortschr Med; 2009 May; 151(19):38-9. PubMed ID: 19827443
[No Abstract] [Full Text] [Related]
9. [Ulcerative colitis. Complementary therapies].
Matthes H; Moser G; Jantschek G
Z Gastroenterol; 2004 Sep; 42(9):1031-2. PubMed ID: 15455282
[No Abstract] [Full Text] [Related]
10. Probiotic therapy with E. coli for ulcerative colitis: take the good with the bad.
Faubion WA; Sandborn WJ
Gastroenterology; 2000 Mar; 118(3):630-1. PubMed ID: 10702217
[No Abstract] [Full Text] [Related]
11. Controversies with aminosalicylates in inflammatory bowel disease.
Lim WC; Hanauer SB
Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
[TBL] [Abstract][Full Text] [Related]
12. [Probiotics for prevention of ulcerative colitis recurrence: alternative medicine added to standard treatment?].
Folwaczny C
Z Gastroenterol; 2000 Jun; 38(6):547-50. PubMed ID: 10923365
[No Abstract] [Full Text] [Related]
13. Trends in inflammatory bowel disease therapy.
Thomson AB; Williams CN
Can J Gastroenterol; 1999 Nov; 13(9):775-6. PubMed ID: 10633831
[No Abstract] [Full Text] [Related]
14. [Maintaining a remission].
Fleig WE;
Z Gastroenterol; 2003 Jan; 41(1):36-42. PubMed ID: 12541172
[No Abstract] [Full Text] [Related]
15. Medical treatment of inflammatory bowel disease.
Singhal A; Kar P
J Assoc Physicians India; 1995 Sep; 43(9):627-31. PubMed ID: 8773067
[No Abstract] [Full Text] [Related]
16. Rifaximin for inflammatory bowel disease.
Guslandi M
Dig Dis Sci; 2010 Jun; 55(6):1805. PubMed ID: 20428944
[No Abstract] [Full Text] [Related]
17. [Bacterially induced traveler's diarrhea. Local antibiosis effective without systemic effects].
MMW Fortschr Med; 2008 Nov; 150(45):48-9. PubMed ID: 19058391
[No Abstract] [Full Text] [Related]
18. Accidentally ASCENDing into comparative effective research for inflammatory bowel disease.
Siegel CA
Gastroenterology; 2009 Dec; 137(6):1880-2. PubMed ID: 19879213
[No Abstract] [Full Text] [Related]
19. [Drug therapy of inflammatory bowel diseases].
Silvennoinen J; Niemelä S
Duodecim; 1999; 115(20):2233-8. PubMed ID: 11973927
[No Abstract] [Full Text] [Related]
20. [Crohn's disease surgery: problems of postoperative recurrence].
Fornaro R; Frascio M; Stabilini C; Sticchi C; Barberis A; Denegri A; Ricci B; Azzinnaro A; Lazzara F; Gianetta E
Chir Ital; 2008; 60(6):761-81. PubMed ID: 19256268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
